
Loading, please wait...

Loading, please wait...

CLOVERS compared two early resuscitation strategies in patients with sepsis-induced hypotension: a restrictive approach that prioritised vasopressors and limited additional fluids, and a liberal approach that prioritised more intravenous fluid before escalating vasopressor support. The trial enrolled patients after an initial period of fluid treatment and followed them to 90 days. Mortality before discharge home by day 90 did not differ significantly between the strategies, and serious adverse-event rates were similar. The findings are useful because they shift the clinical question away from “How many litres should every patient receive?” toward “Which intervention best matches this patient's physiology right now?” Some patients may need additional fluid, while others may have persistent vasodilation and benefit more from vasopressors. The study does not prove that fluids and vasopressors are interchangeable; rather, it demonstrates that two intentionally different resuscitation approaches can produce similar overall outcomes when applied carefully. For clinicians, CLOVERS supports individualised haemodynamic assessment, attention to fluid tolerance and early recognition that ongoing hypotension is not always a sign of inadequate intravascular volume. It also reinforces the importance of avoiding therapeutic inertia—continuing fluids simply because hypotension persists without reassessing the underlying mechanism.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


CLOVERS compared two early resuscitation strategies in patients with sepsis-induced hypotension: a restrictive approach that prioritised vasopressors and limited additional fluids, and a liberal approach that prioritised more intravenous fluid before escalating vasopressor support. The trial enrolled patients after an initial period of fluid treatment and followed them to 90 days. Mortality before discharge home by day 90 did not differ significantly between the strategies, and serious adverse-event rates were similar. The findings are useful because they shift the clinical question away from “How many litres should every patient receive?” toward “Which intervention best matches this patient's physiology right now?” Some patients may need additional fluid, while others may have persistent vasodilation and benefit more from vasopressors. The study does not prove that fluids and vasopressors are interchangeable; rather, it demonstrates that two intentionally different resuscitation approaches can produce similar overall outcomes when applied carefully. For clinicians, CLOVERS supports individualised haemodynamic assessment, attention to fluid tolerance and early recognition that ongoing hypotension is not always a sign of inadequate intravascular volume. It also reinforces the importance of avoiding therapeutic inertia—continuing fluids simply because hypotension persists without reassessing the underlying mechanism.
Today

The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back

A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back

Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back

A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back

A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back